Patients
We included 25 patients, aged 0-21 years with diffuse midline gliomas
who had been treated in the Children’s Hospital of Los Angeles (CHLA)
between September 2000 and December 2012. These patients had citrate
levels measured and recorded in an Institutional Review Board (IRB)
approved database. Their medical records were reviewed retrospectively
for demographic and clinical data including; the date of diagnosis,
diagnosis, extent of resection, treatments received, date of
progression, cause of death and duration of survival, and data was
collected and recorded using a predesigned proforma. Citrate levels and
Crammer-Rao Lower Bounds measurements (CRLB) were obtained from the
previously recorded data in the IRB approved database. The CHLA IRB
approved the study.